FibroScan

Proven sources

Liver diseases a worldwide concern

Viral Hepatitis, Nash, Alcoholism, Haemocromatosis, Diabetes, Mucovisidose are all related to fibrosis

WHO estimates that 3% of the worlds population are infected with HCV and are at risk of developing liver cirrhosis and/ or liver cancer. And that of the 2 billion people who have been infected with the hepatitis B virus (HBV), more than 350 million have chronic (lifelong) infections.
From all around the world, more and more experts bring their testimonies on the FibroScan and its dedicated probe efficiency on different diseases such as:
Liver diSeaSe

Transient elastography can be performed for the staging of liver fibrosis independent from the underlyng liver disease
M. Friedrich-rust et Al., eAsl 2007. Liver compLicaTionS

The FibroScan is a potentially useful adjunct to assess risk of liver decompensation and complications among liver cancer patients undergoing liver resection
l. lAi et Al., APAsl 2007. ( LT x ) T r a n S p L a n TaT i o n

el FibroScan es un mtodo simple para cuantificar el grado de FH en pacientes trasplantados hepticos

J.c. MArn GAbriel et Al., Aeeh 2007. co-inFecTion diSeaSeS (Hiv)

our study confirms the relevance of FibroScan to evaluate fibrosis in Hiv/HBv co-infected patients
P. MiAilhes et Al., crOi 2007.

echosens | Fibroscan Proven sources

More than 250 FibroScan are used all around the world.

echosens | Fibroscan Proven sources

CHrONiC HePaTiTis C
ZiOl et al.

Non invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis C.
Hepatology 2005 | vol. 41, n 1, 2005
summary Keys points D o c a s s o c i at e D

quantification is the key indicator in chronic liver disease evaluation. } Good correlation between FibroScan and Biopsy. Distinguish clearly significant (F2) fibrosis from other } Accurate for cirrhosis stages. diagnosis. } Establish strong performance on cirrhosis diagnosis. (F4) } Show limits of the biopsy } Optimal cut off for FibroScan F2: 8.7kPa (sensi.: 0.55 ; due to the sample size speci.: 0.84) and F4: 14.5 kPa (sensi.: 0.84 ; speci.: 0.94). and then a potential } This study also establishes that in CHC, the correlation underestimation of the between liver stiffness and fibrosis stage is not affected FibroScan results.
} Multicentric French study with 251 patients with chronic

hepatitis C. Correlation FibroScan vs biopsy.

} Fibrosis

} Takada et al. Gastroenterology 2006.12:7768-7773. } Abstract De Ldinghen et al. AASLD 2006 x2.

by steatosis or activity grade.

cAsterA et al.

Prospective comparison of Transient Elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
Gastroenterology 2005 | 128:343-350.
summary Keys points D o c a s s o c i at e D

} Monocentric French study with 183 patients with chronic

hepatitis C.

} Accurate

for cirrhosis diagnosis.

} Compare diagnosis accuracy between, FibroTest, APRI

and FibroScan as combined vs. biopsy.

} Poster EASL 2006 complete 1st study with lok index and oral presentation to DDW 2006 FIBROSCAN best in cirrhosis. } Abstract Serjo et al. AASLD 2006.

} Optimal cut off for FibroScan F2: 7.1 kPa (sensi.: 0.67 ;

speci.: 0.89) and F4: 12.5 kPa (sensi : 0.87 ; speci.: 0.91).

} The best result obtained for F2 was a combination of

FibroScan and FibroTest. But for F4 detection, the FibroScan stand-alone achieves the best performance.

BiLiarY diseases
cOrPechOt et al.

Assessment of Biliary Fibrosis by Transient Elastography in Patients with PBC and PSC.
Hepatology 2006 | 43:1118-1124.
summary Keys points D o c a s s o c i at e D

} Multicentric French study with 95 patients with biliary

cirrhosis or primary sclerosing cholangitis.

} Reliable

} Assess the diagnosis performance of FibroScan to

determine the fibrosis stage in chronic cholestatic diseases with metavir and Ludwig score.

} Excellent correlation between FibroScan and Biopsy.

Results are even better than those reported on HCV.

} FibroScan is more accurate than any other non-invasive

and simple tool to assess liver fibrosis in different stages with chronic cholestatic diseases. } Accurate for assessing fibrosis stage in different chronic liver diseases.

} Abstract GomezDomingez AASLD 2006.

tests. PBC validated and 1 accurate report on PSC.

} Optimal cut off for FibroScan F2: 7.3 kPa (sensi.: 0.82 ;

speci.: 0.79) and F4: 17.3 kPa (sensi.: 0.87 ; speci.: 0.95).

echosens | Fibroscan Proven sources

HCv-Hiv CO-iNFeCTiON
de ledinGhen et al.

Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C VirusCo-infected Patients
JAIDS 2005 | 43:1118-1124.
summary Keys points D o c a s s o c i at e D

can be the first line of therapeutic evaluation in HIV-HCV } The study establishes that liver stiffness is significantly co-infected patients. correlated to Liver fibrosis also in co-infected patients. } Direct/applicable where } Compare to APRI index, AST ALT, FIB-4 and platelet count. other markers fail. } The study demonstrates FibroScan has the best sensibility } Precise, reliable and accurate on cirrhosis diagnosis vs. other tests. for cirrhosis diagnosis. } Optimal cut off for FibroScan: 11.8 kPa for F4 (sensi.: } : no restrictions FS 1.00 ; speci.: 0.93). except ascite.
} Multicentric French study with 72 HIV-HCV co-infected

patients. Assessing liver fibrosis with FibroScan and compare to other non invasive methods.

} FibroScan

} Kelletier et al. J Hepatol 2006;44:5126-5131. } Masaki et al. Hepatol Reasearch 2006;36:135-139.

} FibroScan is not unpaired by treatment, HIV or denutrition

vs. other markers.

bArreirO et al.

Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3
JAIDS 2005 | 43:1118-1124.
summary Keys points D o c a s s o c i at e D

} Monocentic Spanish study with 283 HIV-HCV co-infected

patients.

} Unique.

} 1st time that FibroScan is used as a reference tool of

fibrosis quantification.

} Liver fibrosis progress faster in co-infected patient. The

study looks for the acceleration factor.

FibroScan used as a standard tool. } Precise, reliable and accurate for fibrosis evaluation in chronic liver diseases.

} Abstract De Ldinghen et al. AASLD 2006.

} Highlight usefulness of FibroScan to bring new insights

into natural history of HCV co-infection.

} Gen3, older age and high alamine aminotransferase

level are independent predictors for an advanced liver fibrosis in HIV-HCV patient.

Liver TraNsPLaNTaTiON
cArriOn et al.

Transient Elastography for diagnosis of advance fibrosis and portal hypertension in patients with Hepatitis C recurrence after liver transplantation
Liver transplantation 2006 | 43:1118-1124.
summary Keys points D o c a s s o c i at e D

} Monocentric Spanish study with 124 HCV transplanted

patients.

} Totally

} This study intends to verify that FibroScan can avoid

biopsy after LTx on HCV patients.

} The purpose is to establish a correlation between

FibroScan and HVPG.

} Cost evaluation.

non-invasive. } Repeatable (allow a close monitoring). } Precise, reliable and accurate for cirrhosis diagnosis. } Cost efficient.

} Abstract Rigamonti et al. AASLD 2006.

echosens | Fibroscan Proven sources

CirrHOsis aNd iTs COMPLiCaTiONs

FOucher et al.

Diagnosis of cirrhosis by Transient Elastography (FibroScan): a prospective study.

GUT 2006 | 55:403408.
summary Keys points D o c a s s o c i at e D

for all chronic liver diseases whatever the etiology. } Purpose of the study is to assess the accuracy of FibroScan in cirrhosis detection with chronic liver } Accurate for cirrhosis diseases. diagnosis. } Results establish that stiffness was significantly } Precise as a predictive correlated with fibrosis. Cirrhotic patients were detected factor of complications. with a positive predictive value and a negative
} Monocentric French study with 711 patients with

multiple chronic liver etiologies.

} Accurate

} Ganne-Carrie Hepatol 2006, 44:1511-1517. } Kozemi et al. J Hepatol 2006,45(2):230-235. } Abstract Le moine et al. AASLD 2006.

predictive value of 90%.

} This study establishes a correlation between liver

stiffness and FibroScan.

echosens | Fibroscan Proven sources

What is the unique totally non-invasive device able to detect liver fibrosis whatever the etiology?

Have you ever use or try to use the FibroScan ? *

FibroScan
FS 502

and its dedicated probe

THe firsT And only ToTAlly non-inVAsiVe HepATiC fiBrosis diAgnosTiC And moniToring deViCe

echosens | Fibroscan Proven sources

*for furTHer informATion - CommuniCATion@eCHosens.Com www.eCHosens.Com

153 avenue diTaLie Fr-75013 pariS T. + 33 1 44 82 78 50 F. + 33 1 44 82 78 60

c/ rodrguez San pedro 42 1c eS-28015 madrid T. +34 91 544 7325 F. +34 91 544 7302

poppenBTTeLer STraSSe 170 de-22851 norderSTedT T. +49 (0) 40 50 79 12 00 F. +49 (0) 40 50 79 11 44

www.eCHosens.Com

List of our Distributors arounD the worLD

CANADA

Kns Inc. Furui Professional Medica Artemis Chong Lap

ITALY

Axsan Intermedical Co. Ltd Acme Medical Inc. Eramedic Temco

rUSSIA

Delrus Transmedic Medigiant Sandhill Scientific Khan Thien Trading Cie Ltd

CHINA

JAPAN

SINGAPorE

EGYPT

KorEA

TAIWAN

ENGLAND

MArroCo

USA

HoNG KoNG

roMANIA

VIETNAM

communication@echosens.com

e c h o s e n s , t h e e c h o s e n s l o g o, F i b r o s c a n a n d t h e F i b r o s c a n l o g o a r e r e g i s t e r e d t r a d e m a r k s o F e c h o s e n s c o m Pa n y 2 0 0 7 , e c h o s e n s , Pa r i s , 7 5 0 1 3 - P s 2 0 0 7- 0 7 e n

HeadquarTerS - 42 rue monge - Fr-75005 pariS capiTaL aSSeTS : 162 603.00 - vaT: Fr63 438 209 157